Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Iconic Italian writer Dante Alighieri penned his classic text 'Inferno' during the 14th century, the first part of his famed ...

A woman from Long Island was traveling over the holidays when she lost a beloved piece of jewelry that had been in her family for nearly a century -- and a group of strangers worked together to help ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Gary Stibel is the founder, CEO, and managing partner of the New England Consulting Group. With over half a century of experience, Gary has worked in nearly every segment of the healthcare and life ...

Recent years’ equity mutual fund performance trends trembled in 2024’s fourth quarter but held for the full year. Growth and ...

In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

Still, by my count, this year marks the first time in the 21st century that obesity ... One reason to think that this time is ...

With demand for GLP-1 drugs booming, compounding pharmacies and telehealth ... The AP is solely responsible for all content. For more than a century, Times Union photographers have been documenting ...

People with diabetes may have a lower risk of serious clots with GLP-1 drugs than with some other diabetes medications, a new study finds. People with diabetes may get fewer serious blood clots ...